메뉴 건너뛰기




Volumn 16, Issue 5, 2016, Pages 275-287

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA; IPILIMUMAB; NIVOLUMAB; PROGRAMMED DEATH 1 RECEPTOR; CD274 PROTEIN, HUMAN; CTLA4 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER;

EID: 84963621254     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2016.36     Document Type: Review
Times cited : (2143)

References (125)
  • 1
    • 84858766182 scopus 로고    scopus 로고
    • The blockade of immune checkpoints in cancer immunotherapy
    • Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
    • (2012) Nat. Rev. Cancer , vol.12 , pp. 252-264
    • Pardoll, D.M.1
  • 2
    • 84940379785 scopus 로고    scopus 로고
    • Cancer and the immune system: Basic concepts and targets for intervention
    • Pardoll, D. Cancer and the immune system: basic concepts and targets for intervention. Semin. Oncol. 42, 523-538 (2015).
    • (2015) Semin. Oncol , vol.42 , pp. 523-538
    • Pardoll, D.1
  • 3
    • 84898973055 scopus 로고    scopus 로고
    • Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
    • Topalian, S. L. et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32, 1020-1030 (2014).
    • (2014) J. Clin. Oncol , vol.32 , pp. 1020-1030
    • Topalian, S.L.1
  • 4
    • 84879759020 scopus 로고    scopus 로고
    • Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
    • Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134-144 (2013).
    • (2013) N. Engl. J. Med , vol.369 , pp. 134-144
    • Hamid, O.1
  • 5
    • 84929481481 scopus 로고    scopus 로고
    • Pembrolizumab versus ipilimumab in advanced melanoma
    • Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521-2532 (2015).
    • (2015) N. Engl. J. Med , vol.372 , pp. 2521-2532
    • Robert, C.1
  • 6
    • 84925222119 scopus 로고    scopus 로고
    • Nivolumab in previously untreated melanoma without BRAF mutation
    • Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320-330 (2015).
    • (2015) N. Engl. J. Med , vol.372 , pp. 320-330
    • Robert, C.1
  • 7
    • 84936147067 scopus 로고    scopus 로고
    • Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
    • Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23-34 (2015).
    • (2015) N. Engl. J. Med , vol.373 , pp. 23-34
    • Larkin, J.1
  • 8
    • 84929481480 scopus 로고    scopus 로고
    • Pembrolizumab for the treatment of non-small-cell lung cancer
    • Garon, E. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018-2028 (2015).
    • (2015) N. Engl. J. Med , vol.372 , pp. 2018-2028
    • Garon, E.1
  • 9
    • 84936791837 scopus 로고    scopus 로고
    • Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
    • Brahmer, J. R. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123-135 (2015).
    • (2015) N. Engl. J. Med , vol.373 , pp. 123-135
    • Brahmer, J.R.1
  • 10
    • 84944937210 scopus 로고    scopus 로고
    • Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
    • Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627-1639 (2015).
    • (2015) N. Engl. J. Med , vol.373 , pp. 1627-1639
    • Borghaei, H.1
  • 11
    • 84929572937 scopus 로고    scopus 로고
    • Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial
    • Motzer, R. J. et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J. Clin. Oncol. 33, 1430-1437 (2015).
    • (2015) J. Clin. Oncol , vol.33 , pp. 1430-1437
    • Motzer, R.J.1
  • 12
    • 84946607195 scopus 로고    scopus 로고
    • Nivolumab versus everolimus in advanced renal-cell carcinoma
    • Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803-1813 (2015).
    • (2015) N. Engl. J. Med , vol.373 , pp. 1803-1813
    • Motzer, R.J.1
  • 13
    • 84929342210 scopus 로고    scopus 로고
    • Antagonists of PD-1 and PD-L1 in cancer treatment
    • Lipson, E. J. et al. Antagonists of PD-1 and PD-L1 in cancer treatment. Semin. Oncol. 42, 587-600 (2015).
    • (2015) Semin. Oncol , vol.42 , pp. 587-600
    • Lipson, E.J.1
  • 14
    • 84862859820 scopus 로고    scopus 로고
    • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
    • The report of this large early-phase clinical study demonstrates a role for anti-PD1 therapy in NSCLC, melanoma and kidney cancer, but not in prostate cancer or CRC; it also provides the first demonstration of PDL1 IHC as a potential biomarker for anti-PD1 therapy
    • Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012). The report of this large early-phase clinical study demonstrates a role for anti-PD1 therapy in NSCLC, melanoma and kidney cancer, but not in prostate cancer or CRC; it also provides the first demonstration of PDL1 IHC as a potential biomarker for anti-PD1 therapy.
    • (2012) N. Engl. J. Med , vol.366 , pp. 2443-2454
    • Topalian, S.L.1
  • 15
    • 84928062583 scopus 로고    scopus 로고
    • Immune checkpoint blockade: A common denominator approach to cancer therapy
    • Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450-461 (2015).
    • (2015) Cancer Cell , vol.27 , pp. 450-461
    • Topalian, S.L.1    Drake, C.G.2    Pardoll, D.M.3
  • 16
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
    • (2010) N. Engl. J. Med , vol.363 , pp. 711-723
    • Hodi, F.S.1
  • 17
    • 84928917822 scopus 로고    scopus 로고
    • Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma
    • Schadendorf, D. et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33, 1889-1894 (2015).
    • (2015) J. Clin. Oncol , vol.33 , pp. 1889-1894
    • Schadendorf, D.1
  • 18
    • 32544459770 scopus 로고    scopus 로고
    • Restoring function in exhausted CD8 T cells during chronic viral infection
    • Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682-687 (2006).
    • (2006) Nature , vol.439 , pp. 682-687
    • Barber, D.L.1
  • 19
    • 84920956732 scopus 로고    scopus 로고
    • PD-1 blockade induces responses by inhibiting adaptive immune resistance
    • Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
    • (2014) Nature , vol.515 , pp. 568-571
    • Tumeh, P.C.1
  • 20
    • 77954899030 scopus 로고    scopus 로고
    • Phase i study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates
    • This first-in-human study of MDX-1106 (nivolumab) reports early evidence for clinical activity in multiple cancer types, pharmacodynamics and PDL1 IHC as a predictor of clinical outcomes
    • Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167-3175 (2010). This first-in-human study of MDX-1106 (nivolumab) reports early evidence for clinical activity in multiple cancer types, pharmacodynamics and PDL1 IHC as a predictor of clinical outcomes.
    • (2010) J. Clin. Oncol , vol.28 , pp. 3167-3175
    • Brahmer, J.R.1
  • 21
    • 84906510279 scopus 로고    scopus 로고
    • Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
    • Robert, L. et al. Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. Oncoimmunology 3, e29244 (2014).
    • (2014) Oncoimmunology , vol.3
    • Robert, L.1
  • 22
    • 28244492012 scopus 로고    scopus 로고
    • Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade
    • Maker, A. V., Attia, P. & Rosenberg, S. A. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol. 175, 7746-7754 (2005).
    • (2005) J. Immunol , vol.175 , pp. 7746-7754
    • Maker, A.V.1    Attia, P.2    Rosenberg, S.A.3
  • 23
    • 77950258677 scopus 로고    scopus 로고
    • Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: Lymphocyte count after 2 doses correlates with survival
    • Ku, G. Y. et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 116, 1767-1775 (2010).
    • (2010) Cancer , vol.116 , pp. 1767-1775
    • Ku, G.Y.1
  • 24
    • 78449244712 scopus 로고    scopus 로고
    • CTLA-4 blockade with ipilimumab increases peripheral CD8+ T cells: Correlation with clinical outcomes
    • Yang, A. et al. CTLA-4 blockade with ipilimumab increases peripheral CD8+ T cells: correlation with clinical outcomes. J. Clin. Oncol. 28 (15 suppl.), 2555 (2010).
    • (2010) J. Clin. Oncol , vol.28 , Issue.15 , pp. 2555
    • Yang, A.1
  • 25
    • 58149483422 scopus 로고    scopus 로고
    • CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
    • Yuan, J. et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl Acad. Sci. USA 105, 20410-20415 (2008).
    • (2008) Proc. Natl Acad. Sci. USA , vol.105 , pp. 20410-20415
    • Yuan, J.1
  • 26
    • 80053648839 scopus 로고    scopus 로고
    • Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
    • Yuan, J. et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc. Natl Acad. Sci. USA 108, 16723-16728 (2011).
    • (2011) Proc. Natl Acad. Sci. USA , vol.108 , pp. 16723-16728
    • Yuan, J.1
  • 27
    • 84961290760 scopus 로고    scopus 로고
    • Anticancer immunotherapy by CTLA-4 blockade: Obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
    • Hannani, D. et al. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res. 25, 208-224 (2015).
    • (2015) Cell Res , vol.25 , pp. 208-224
    • Hannani, D.1
  • 28
    • 84862769116 scopus 로고    scopus 로고
    • An immune-active tumor microenvironment favors clinical response to ipilimumab
    • Ji, R. R. et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother. 61, 1019-1031 (2012).
    • (2012) Cancer Immunol. Immunother , vol.61 , pp. 1019-1031
    • Ji, R.R.1
  • 29
    • 62449309334 scopus 로고    scopus 로고
    • Anti-CTLA-4 therapy results in higher CD4+ ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues
    • Chen, H. et al. Anti-CTLA-4 therapy results in higher CD4+ ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc. Natl Acad. Sci. USA 106, 2729-2734 (2009).
    • (2009) Proc. Natl Acad. Sci. USA , vol.106 , pp. 2729-2734
    • Chen, H.1
  • 30
    • 77954230122 scopus 로고    scopus 로고
    • Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment associated modulation of inducible costimulator expression on patient T cells
    • Vonderheide, R. H. et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment associated modulation of inducible costimulator expression on patient T cells. Clin. Cancer Res. 16, 3485-3494 (2010).
    • (2010) Clin. Cancer Res , vol.16 , pp. 3485-3494
    • Vonderheide, R.H.1
  • 31
    • 42949105127 scopus 로고    scopus 로고
    • Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
    • Hodi, F. S. et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl Acad. Sci. USA 105, 3005-3010 (2008).
    • (2008) Proc. Natl Acad. Sci. USA , vol.105 , pp. 3005-3010
    • Hodi, F.S.1
  • 32
    • 54449091476 scopus 로고    scopus 로고
    • CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
    • Liakou, C. I. et al. CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc. Natl Acad. Sci. USA 105, 14987-14992 (2008).
    • (2008) Proc. Natl Acad. Sci. USA , vol.105 , pp. 14987-14992
    • Liakou, C.I.1
  • 34
    • 0035901090 scopus 로고    scopus 로고
    • Inflammation and cancer: Back to Virchow?
    • Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539-545 (2001).
    • (2001) Lancet , vol.357 , pp. 539-545
    • Balkwill, F.1    Mantovani, A.2
  • 35
    • 33749319703 scopus 로고    scopus 로고
    • Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
    • Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 (2006).
    • (2006) Science , vol.313 , pp. 1960-1964
    • Galon, J.1
  • 36
    • 84858800620 scopus 로고    scopus 로고
    • The immune contexture in human tumours: Impact on clinical outcome
    • Fridman, W. H., PagΘs, F., SautΘs-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298-306 (2012).
    • (2012) Nat. Rev. Cancer , vol.12 , pp. 298-306
    • Fridman, W.H.1    Pags, F.2    Sauts-Fridman, C.3    Galon, J.4
  • 37
    • 52449102477 scopus 로고    scopus 로고
    • Long term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures
    • Dieu-Nosjean, M. C. et al. Long term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 26, 4410-4417 (2008).
    • (2008) J. Clin. Oncol , vol.26 , pp. 4410-4417
    • Dieu-Nosjean, M.C.1
  • 38
    • 84896957921 scopus 로고    scopus 로고
    • Occurrence of tertiary lymphoid tissue is associated to T-cell infiltration and predicts better prognosis in early-stage colorectal cancers
    • Di Caro, G. et al. Occurrence of tertiary lymphoid tissue is associated to T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin. Cancer Res. 20, 2147-2158 (2014).
    • (2014) Clin. Cancer Res , vol.20 , pp. 2147-2158
    • Di Caro, G.1
  • 39
    • 84898948823 scopus 로고    scopus 로고
    • Emerging immunologic biomarkers: Setting the (TNM-immune) stage
    • Taube, J. M. Emerging immunologic biomarkers: setting the (TNM-immune) stage. Clin. Cancer Res. 20, 2023-2025 (2014).
    • (2014) Clin. Cancer Res , vol.20 , pp. 2023-2025
    • Taube, J.M.1
  • 40
    • 0032736029 scopus 로고    scopus 로고
    • B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
    • Dong, H., Zhu, G., Tamada, K. & Chen, L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5, 1365-1369 (1999).
    • (1999) Nat. Med , vol.5 , pp. 1365-1369
    • Dong, H.1    Zhu, G.2    Tamada, K.3    Chen, L.4
  • 41
    • 18544380239 scopus 로고    scopus 로고
    • Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
    • Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793-800 (2002).
    • (2002) Nat. Med , vol.8 , pp. 793-800
    • Dong, H.1
  • 42
    • 0036785604 scopus 로고    scopus 로고
    • B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis
    • Mazanet, M. M. & Hughes, C. C. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J. Immunol. 169, 3581-3588 (2002).
    • (2002) J. Immunol , vol.169 , pp. 3581-3588
    • Mazanet, M.M.1    Hughes, C.C.2
  • 43
    • 33846118474 scopus 로고    scopus 로고
    • Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
    • Parsa, A. T. et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat. Med. 13, 84-88 (2007).
    • (2007) Nat. Med , vol.13 , pp. 84-88
    • Parsa, A.T.1
  • 44
    • 78049370405 scopus 로고    scopus 로고
    • Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
    • Green, M. R. et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116, 3268-3277 (2010).
    • (2010) Blood , vol.116 , pp. 3268-3277
    • Green, M.R.1
  • 45
    • 84925221855 scopus 로고    scopus 로고
    • PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
    • Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372, 311-319 (2015).
    • (2015) N. Engl. J. Med , vol.372 , pp. 311-319
    • Ansell, S.M.1
  • 46
    • 84859128199 scopus 로고    scopus 로고
    • Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape
    • This report provides the first evidence for, and articulation of, the adaptive immune resistance hypothesis
    • Taube, J. M. et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl Med. 4, 127ra37 (2012). This report provides the first evidence for, and articulation of, the adaptive immune resistance hypothesis.
    • (2012) Sci. Transl Med , vol.4
    • Taube, J.M.1
  • 47
    • 84942887332 scopus 로고    scopus 로고
    • Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: Implications for PD-1 pathway blockade
    • Taube, J. M. et al. Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade. Clin. Cancer Res. 21, 3969-3976 (2015).
    • (2015) Clin. Cancer Res , vol.21 , pp. 3969-3976
    • Taube, J.M.1
  • 48
    • 84891528539 scopus 로고    scopus 로고
    • PD-L1 expression in the Merkel cell carcinoma microenvironment: Association with inflammation, Merkel cell polyomavirus and overall survival
    • Lipson, E. J. et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol. Res. 1, 54-63 (2013).
    • (2013) Cancer Immunol. Res , vol.1 , pp. 54-63
    • Lipson, E.J.1
  • 49
    • 84891534246 scopus 로고    scopus 로고
    • Programmed death ligand-1 expression in non-small cell lung cancer
    • Velcheti, V. et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab. Invest. 94, 107-116 (2014).
    • (2014) Lab. Invest , vol.94 , pp. 107-116
    • Velcheti, V.1
  • 50
    • 84901044976 scopus 로고    scopus 로고
    • In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas
    • Schalper, K. A. et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin. Cancer Res. 20, 2773-2782 (2014).
    • (2014) Clin. Cancer Res , vol.20 , pp. 2773-2782
    • Schalper, K.A.1
  • 51
    • 84951856362 scopus 로고    scopus 로고
    • PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
    • Cimino-Mathews, A. et al. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum. Pathol. 47, 52-63 (2016).
    • (2016) Hum. Pathol , vol.47 , pp. 52-63
    • Cimino-Mathews, A.1
  • 52
    • 84875475811 scopus 로고    scopus 로고
    • Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma
    • Lyford-Pike, S. et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 73, 1733-1741 (2013).
    • (2013) Cancer Res , vol.73 , pp. 1733-1741
    • Lyford-Pike, S.1
  • 53
    • 84938794719 scopus 로고    scopus 로고
    • Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities
    • Skoulidis, F. et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 5, 860-877 (2015).
    • (2015) Cancer Discov , vol.5 , pp. 860-877
    • Skoulidis, F.1
  • 54
    • 84962232340 scopus 로고    scopus 로고
    • PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation
    • Rodic, N. et al. PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation. Cancer Immunol. Res. 3, 110-115 (2015).
    • (2015) Cancer Immunol. Res , vol.3 , pp. 110-115
    • Rodic, N.1
  • 55
    • 84880507665 scopus 로고    scopus 로고
    • Mutational heterogeneity in cancer and the search for new cancer-associated genes
    • Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
    • (2013) Nature , vol.499 , pp. 214-218
    • Lawrence, M.S.1
  • 56
    • 84922369377 scopus 로고    scopus 로고
    • The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints
    • Llosa, N. J. et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 5, 43-51 (2015).
    • (2015) Cancer Discov , vol.5 , pp. 43-51
    • Llosa, N.J.1
  • 57
    • 33645736792 scopus 로고    scopus 로고
    • Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up
    • Thompson, R. H. et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 66, 3381-3385 (2006).
    • (2006) Cancer Res , vol.66 , pp. 3381-3385
    • Thompson, R.H.1
  • 58
    • 84904024273 scopus 로고    scopus 로고
    • Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
    • Taube, J. M. et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20, 5064-5074 (2014).
    • (2014) Clin. Cancer Res , vol.20 , pp. 5064-5074
    • Taube, J.M.1
  • 59
    • 84872514622 scopus 로고    scopus 로고
    • Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody
    • Lipson, E. J. et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin. Cancer Res. 19, 462-468 (2013).
    • (2013) Clin. Cancer Res , vol.19 , pp. 462-468
    • Lipson, E.J.1
  • 60
    • 84962150072 scopus 로고    scopus 로고
    • Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma
    • Thompson, E. D. et al. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut http://dx.doi.org/10.1136/gutjnl-2015-310839 (2016).
    • (2016) Gut
    • Thompson, E.D.1
  • 62
    • 84920956735 scopus 로고    scopus 로고
    • Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
    • Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567 (2014).
    • (2014) Nature , vol.515 , pp. 563-567
    • Herbst, R.S.1
  • 63
    • 84962497081 scopus 로고    scopus 로고
    • Atezolizumab, and anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: Long-term safety, clinical activity and immune correlates from a phase Ia study
    • McDermott, D. F. et al. Atezolizumab, and anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity and immune correlates from a phase Ia study. J. Clin. Oncol. 34, 833-842 (2016).
    • (2016) J. Clin. Oncol , vol.34 , pp. 833-842
    • McDermott, D.F.1
  • 64
    • 84941418939 scopus 로고    scopus 로고
    • Reliability of small biopsy samples compared with resected specimens for the determination of programmed death-ligand 1 expression in non-small-cell lung cancer
    • Kitazono, S. et al. Reliability of small biopsy samples compared with resected specimens for the determination of programmed death-ligand 1 expression in non-small-cell lung cancer. Clin. Lung Cancer 16, 385-390 (2015).
    • (2015) Clin. Lung Cancer , vol.16 , pp. 385-390
    • Kitazono, S.1
  • 65
    • 0004245975 scopus 로고    scopus 로고
    • (ed. Dabbs, D. J.), Churchill Livingstone
    • Dabbs, D. J. in Diagnostic immunohistochemistry (ed. Dabbs, D. J.) 29-39 (Churchill Livingstone, 2002).
    • (2002) Diagnostic Immunohistochemistry , pp. 29-39
    • Dabbs, D.J.1
  • 66
    • 0034900416 scopus 로고    scopus 로고
    • The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma
    • Von Mehren, M. et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin. Cancer Res. 7, 1181-1189 (2001).
    • (2001) Clin. Cancer Res , vol.7 , pp. 1181-1189
    • Von Mehren, M.1
  • 67
    • 84962205403 scopus 로고    scopus 로고
    • The interplay of immunotherapy and chemotherapy: Harnessing potential synergies
    • Emens, L. A. & Middleton, G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol. Res. 3, 436-443 (2015).
    • (2015) Cancer Immunol. Res , vol.3 , pp. 436-443
    • Emens, L.A.1    Middleton, G.2
  • 68
    • 84880452562 scopus 로고    scopus 로고
    • Genomics-driven oncology: Framework for an emerging paradigm
    • Garraway, L. A. Genomics-driven oncology: framework for an emerging paradigm. J. Clin. Oncol. 31, 1806-1814 (2013).
    • (2013) J. Clin. Oncol , vol.31 , pp. 1806-1814
    • Garraway, L.A.1
  • 69
    • 33745859743 scopus 로고    scopus 로고
    • The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
    • Sumimoto, H., Imabayashi, F., Iwata, T. & Kawakami, Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med. 203, 1651-1656 (2006).
    • (2006) J. Exp. Med , vol.203 , pp. 1651-1656
    • Sumimoto, H.1    Imabayashi, F.2    Iwata, T.3    Kawakami, Y.4
  • 70
    • 58549102319 scopus 로고    scopus 로고
    • Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
    • Marzec, M. et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc. Natl Acad. Sci. USA 105, 20852-20857 (2008).
    • (2008) Proc. Natl Acad. Sci. USA , vol.105 , pp. 20852-20857
    • Marzec, M.1
  • 71
    • 84890020587 scopus 로고    scopus 로고
    • Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors
    • Akbay, E. A. et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 3, 1355-1363 (2013).
    • (2013) Cancer Discov , vol.3 , pp. 1355-1363
    • Akbay, E.A.1
  • 72
    • 84900393562 scopus 로고    scopus 로고
    • Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression
    • Xu, C. et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell 25, 590-604 (2014).
    • (2014) Cancer Cell , vol.25 , pp. 590-604
    • Xu, C.1
  • 73
    • 84980602745 scopus 로고    scopus 로고
    • Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: A pooled analysis of 4 clinical trials
    • Larkin, J. et al. Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol. 1, 433-440 (2015).
    • (2015) JAMA Oncol , vol.1 , pp. 433-440
    • Larkin, J.1
  • 74
    • 84931083080 scopus 로고    scopus 로고
    • Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomized, controlled, open-label phase 3 trial
    • Weber, J. S. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomized, controlled, open-label phase 3 trial. Lancet Oncol. 16, 375-384 (2015).
    • (2015) Lancet Oncol , vol.16 , pp. 375-384
    • Weber, J.S.1
  • 75
    • 84950998405 scopus 로고    scopus 로고
    • Efficacy of pembrolizumab in key subgroups of patients with advanced NSCLC
    • abstract MINI03.05
    • Hellmann, M. D. et al. Efficacy of pembrolizumab in key subgroups of patients with advanced NSCLC. J. Thor. Oncol. 10 (suppl. 2) abstract MINI03.05 (2015).
    • (2015) J. Thor. Oncol , vol.10
    • Hellmann, M.D.1
  • 76
    • 84928770388 scopus 로고    scopus 로고
    • Neoantigens in cancer immunotherapy
    • Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science. 348, 69-74 (2015).
    • (2015) Science , vol.348 , pp. 69-74
    • Schumacher, T.N.1    Schreiber, R.D.2
  • 77
    • 26244467481 scopus 로고    scopus 로고
    • All the peptides that fit: The beginning, the middle, and the end of the MHC class i antigen-processing pathway
    • Shastri, N., Cardinaud, S., Schwab, S. T., Serwold, T. & Kunisawa, J. All the peptides that fit: the beginning, the middle, and the end of the MHC class I antigen-processing pathway. Immunol. Rev. 207, 31-41 (2005).
    • (2005) Immunol. Rev , vol.207 , pp. 31-41
    • Shastri, N.1    Cardinaud, S.2    Schwab, S.T.3    Serwold, T.4    Kunisawa, J.5
  • 78
    • 84925732779 scopus 로고    scopus 로고
    • The ins and outs of MHC class II-mediated antigen processing and presentation
    • Roche, P. A. & Furata, K. The ins and outs of MHC class II-mediated antigen processing and presentation. Nat. Rev. Immunol. 15, 203-216 (2015).
    • (2015) Nat. Rev. Immunol , vol.15 , pp. 203-216
    • Roche, P.A.1    Furata, K.2
  • 79
    • 84862903106 scopus 로고    scopus 로고
    • Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
    • This article reports the first demonstration of clinical activity of a drug to block PDL1; a companion article in the same journal issue (ref. 14) describes a different drug that blocks PD1; together these papers highlight the PD1-PDL1 pathway as a vital target in cancer immunotherapy
    • Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012). This article reports the first demonstration of clinical activity of a drug to block PDL1; a companion article in the same journal issue (ref. 14) describes a different drug that blocks PD1; together these papers highlight the PD1-PDL1 pathway as a vital target in cancer immunotherapy.
    • (2012) N. Engl. J. Med , vol.366 , pp. 2455-2465
    • Brahmer, J.R.1
  • 80
    • 84918828514 scopus 로고    scopus 로고
    • Genetic basis for clinical response to CTLA-4 blockade in melanoma
    • Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189-2199 (2014).
    • (2014) N. Engl. J. Med , vol.371 , pp. 2189-2199
    • Snyder, A.1
  • 81
    • 84943516465 scopus 로고    scopus 로고
    • Genomic correlates of response to CTLA4 blockade in metastatic melanoma
    • Van Allen, E. M. et al. Genomic correlates of response to CTLA4 blockade in metastatic melanoma. Science 350, 207-211 (2015).
    • (2015) Science , vol.350 , pp. 207-211
    • Van Allen, E.M.1
  • 82
    • 84928761118 scopus 로고    scopus 로고
    • Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
    • Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
    • (2015) Science , vol.348 , pp. 124-128
    • Rizvi, N.A.1
  • 83
    • 84926525215 scopus 로고    scopus 로고
    • Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
    • Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373-377 (2015).
    • (2015) Nature , vol.520 , pp. 373-377
    • Twyman-Saint Victor, C.1
  • 84
    • 84920921528 scopus 로고    scopus 로고
    • Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
    • Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577-581 (2014).
    • (2014) Nature , vol.515 , pp. 577-581
    • Gubin, M.M.1
  • 85
    • 84920956731 scopus 로고    scopus 로고
    • Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
    • Yadav, M. et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515, 572-576 (2014).
    • (2014) Nature , vol.515 , pp. 572-576
    • Yadav, M.1
  • 86
    • 84949730499 scopus 로고    scopus 로고
    • Immunogenicity of somatic mutations in human gastrointestinal cancers
    • Tran, E. et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350, 1387-1390 (2015).
    • (2015) Science , vol.350 , pp. 1387-1390
    • Tran, E.1
  • 87
    • 84907284200 scopus 로고    scopus 로고
    • Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response
    • Kvistborg, P. et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci. Transl Med. 6, 254ra128 (2014).
    • (2014) Sci. Transl Med , vol.6
    • Kvistborg, P.1
  • 88
    • 84900301377 scopus 로고    scopus 로고
    • Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer
    • Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641-645 (2014).
    • (2014) Science , vol.344 , pp. 641-645
    • Tran, E.1
  • 89
    • 84894559188 scopus 로고    scopus 로고
    • Tumour antigens recognized by T lymphocytes: At the core of cancer immunotherapy
    • Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P. & Boon, T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat. Rev. Cancer 14, 135-146 (2014).
    • (2014) Nat. Rev. Cancer , vol.14 , pp. 135-146
    • Coulie, P.G.1    Van Den Eynde, B.J.2    Van Der Bruggen, P.3    Boon, T.4
  • 90
    • 2942569549 scopus 로고    scopus 로고
    • Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients
    • Liu, B. et al. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat. Med. 2, 169-174 (1996).
    • (1996) Nat. Med , vol.2 , pp. 169-174
    • Liu, B.1
  • 91
    • 0030592517 scopus 로고    scopus 로고
    • Lessons from hereditary colorectal cancer
    • Kinzler, K. W. & Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 87, 159-170 (1996).
    • (1996) Cell , vol.87 , pp. 159-170
    • Kinzler, K.W.1    Vogelstein, B.2
  • 92
    • 68449099031 scopus 로고    scopus 로고
    • Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer
    • Drescher, K. M. et al. Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer. Fam. Cancer 8, 231-239 (2009).
    • (2009) Fam. Cancer , vol.8 , pp. 231-239
    • Drescher, K.M.1
  • 93
    • 84932628341 scopus 로고    scopus 로고
    • PD-1 Blockade in tumors with mismatch-repair deficiency
    • This is the first report linking a genetic marker in cancer (MSI) with clinical outcomes following anti-PD1 therapy
    • Le, D. T. et al. PD-1 Blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509-2520 (2015). This is the first report linking a genetic marker in cancer (MSI) with clinical outcomes following anti-PD1 therapy.
    • (2015) N. Engl. J. Med , vol.372 , pp. 2509-2520
    • Le, D.T.1
  • 94
    • 84964683305 scopus 로고    scopus 로고
    • Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma
    • Sukowati, C. H. et al. Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma. World J. Gastroenterol. 22, 1497-1512 (2016).
    • (2016) World J. Gastroenterol , vol.22 , pp. 1497-1512
    • Sukowati, C.H.1
  • 95
    • 0027355791 scopus 로고
    • Epstein-Barr virus and nasopharyngeal carcinoma
    • Pearson, G. R. Epstein-Barr virus and nasopharyngeal carcinoma. J. Cell. Biochem. Suppl. 17, 150-154 (1993).
    • (1993) J. Cell. Biochem. Suppl , vol.17 , pp. 150-154
    • Pearson, G.R.1
  • 96
    • 33745004866 scopus 로고    scopus 로고
    • Human papillomavirus vaccines
    • Stanley, M. A. Human papillomavirus vaccines. Rev. Med. Virol. 16, 139-149 (2006).
    • (2006) Rev. Med. Virol , vol.16 , pp. 139-149
    • Stanley, M.A.1
  • 97
    • 64249163284 scopus 로고    scopus 로고
    • Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions
    • Hoots, B. E., Palefsky, J. M., Pimenta, J. M. & Smith, J. S. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int. J. Cancer 124, 2375-2383 (2009).
    • (2009) Int. J. Cancer , vol.124 , pp. 2375-2383
    • Hoots, B.E.1    Palefsky, J.M.2    Pimenta, J.M.3    Smith, J.S.4
  • 98
    • 27444431583 scopus 로고    scopus 로고
    • Human T-cell leukemia virus type i (HTLV-I) infection and the onset of adult T-cell leukemia (ATL)
    • Matsuoka, M. Human T-cell leukemia virus type I (HTLV-I) infection and the onset of adult T-cell leukemia (ATL). Retrovirology 2, 27 (2005).
    • (2005) Retrovirology , vol.2 , pp. 27
    • Matsuoka, M.1
  • 99
    • 76849087997 scopus 로고    scopus 로고
    • Kaposi sarcoma-associated herpesvirus (KSHV): Molecular biology and oncogenesis
    • Wen, K. W. & Damania, B. Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis. Cancer Lett. 289, 140-150 (2010).
    • (2010) Cancer Lett , vol.289 , pp. 140-150
    • Wen, K.W.1    Damania, B.2
  • 100
    • 84940642537 scopus 로고    scopus 로고
    • Epstein-Barr virus infection and gastric cancer: A systematic review
    • Chen, X. Z., Chen, H., Castro, F. A., Hu, J. K. & Brenner, H. Epstein-Barr virus infection and gastric cancer: a systematic review. Medicine 94, e792 (2015).
    • (2015) Medicine , vol.94 , pp. e792
    • Chen, X.Z.1    Chen, H.2    Castro, F.A.3    Hu, J.K.4    Brenner, H.5
  • 101
    • 0023425376 scopus 로고
    • Lymphoproliferative diseases in immunocompromised hosts: The role of Epstein-Barr virus
    • List, A. F., Greco, F. A. & Vogler, L. B. Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein-Barr virus. J. Clin. Oncol. 5, 1673-1689 (1987).
    • (1987) J. Clin. Oncol , vol.5 , pp. 1673-1689
    • List, A.F.1    Greco, F.A.2    Vogler, L.B.3
  • 102
    • 37149031657 scopus 로고    scopus 로고
    • Contribution of the Epstein-Barr virus to the molecular pathogenesis of Hodgkin lymphoma
    • Kapatai, G. & Murray, P. Contribution of the Epstein-Barr virus to the molecular pathogenesis of Hodgkin lymphoma. J. Clin. Pathol. 60, 1342-1349 (2007).
    • (2007) J. Clin. Pathol , vol.60 , pp. 1342-1349
    • Kapatai, G.1    Murray, P.2
  • 103
    • 84926302010 scopus 로고    scopus 로고
    • Merkel cell polyomavirus in Merkel cell carcinoma: Clinical and therapeutic perspectives
    • Samimi, M. et al. Merkel cell polyomavirus in Merkel cell carcinoma: clinical and therapeutic perspectives. Semin. Oncol. 42, 347-358 (2015).
    • (2015) Semin. Oncol , vol.42 , pp. 347-358
    • Samimi, M.1
  • 104
    • 0034600339 scopus 로고    scopus 로고
    • Evidence for a causal association between human papillomavirus and a subset of head and neck cancers
    • Gillison, M. L. et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Natl Cancer Inst. 92, 709-720 (2000).
    • (2000) J. Natl Cancer Inst , vol.92 , pp. 709-720
    • Gillison, M.L.1
  • 105
    • 84964597613 scopus 로고    scopus 로고
    • Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma
    • abstract 22LBA, in the press
    • Nghiem, P. et al. Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma. Ann. Oncol. 27 (suppl.), abstract 22LBA, in the press (2015).
    • (2015) Ann. Oncol , vol.27
    • Nghiem, P.1
  • 106
    • 84937067787 scopus 로고    scopus 로고
    • Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040
    • abstract LBA101
    • El-Khoueiry, A. B. et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J. Clin. Oncol. 33 (15 suppl.), abstract LBA101 (2015).
    • (2015) J. Clin. Oncol , vol.33 , Issue.15
    • El-Khoueiry, A.B.1
  • 107
    • 84956607773 scopus 로고    scopus 로고
    • Immunological effects of conventional chemotherapy and targeted anticancer agents
    • Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28, 690-714 (2015).
    • (2015) Cancer Cell , vol.28 , pp. 690-714
    • Galluzzi, L.1    Buque, A.2    Kepp, O.3    Zitvogel, L.4    Kroemer, G.5
  • 108
    • 84874872137 scopus 로고    scopus 로고
    • BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma
    • Frederick, D. T. et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 19, 1225-1231 (2013).
    • (2013) Clin. Cancer Res , vol.19 , pp. 1225-1231
    • Frederick, D.T.1
  • 109
    • 84940381273 scopus 로고    scopus 로고
    • Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses
    • Chiappinelli, K. B. et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162, 974-986 (2015).
    • (2015) Cell , vol.162 , pp. 974-986
    • Chiappinelli, K.B.1
  • 110
    • 84937846973 scopus 로고    scopus 로고
    • Evolving synergistic combinations of targeted immunotherapies to combat cancer
    • Melero, I. et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat. Rev. Cancer 15, 457-472 (2015).
    • (2015) Nat. Rev. Cancer , vol.15 , pp. 457-472
    • Melero, I.1
  • 111
    • 84879777241 scopus 로고    scopus 로고
    • Nivolumab plus ipilimumab in advanced melanoma
    • This initial report demonstrates the activity and side effect profile of anti-PD1 plus anti-CTLA4 therapy, the first immunotherapy combination to eventually receive FDA approval
    • Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013). This initial report demonstrates the activity and side effect profile of anti-PD1 plus anti-CTLA4 therapy, the first immunotherapy combination to eventually receive FDA approval.
    • (2013) N. Engl. J. Med , vol.369 , pp. 122-133
    • Wolchok, J.D.1
  • 112
    • 84929481482 scopus 로고    scopus 로고
    • Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
    • Postow, M. A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006-2017 (2015).
    • (2015) N. Engl. J. Med , vol.372 , pp. 2006-2017
    • Postow, M.A.1
  • 114
    • 79956103042 scopus 로고    scopus 로고
    • Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors
    • Ngiow, S. F. et al. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res. 71, 3540-3551 (2011).
    • (2011) Cancer Res , vol.71 , pp. 3540-3551
    • Ngiow, S.F.1
  • 115
    • 65349130644 scopus 로고    scopus 로고
    • Fine tuning the immune response through B7-H3 and B7-H4
    • Yi, K. H. & Chen, L. Fine tuning the immune response through B7-H3 and B7-H4. Immunol. Rev. 229, 145-151 (2009).
    • (2009) Immunol. Rev , vol.229 , pp. 145-151
    • Yi, K.H.1    Chen, L.2
  • 116
    • 34250351459 scopus 로고    scopus 로고
    • Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
    • Deaglio, S. et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204, 1257-1265 (2007).
    • (2007) J. Exp. Med , vol.204 , pp. 1257-1265
    • Deaglio, S.1
  • 117
    • 38049141544 scopus 로고    scopus 로고
    • A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells
    • Zarek, P. E. et al. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 111, 251-259 (2008).
    • (2008) Blood , vol.111 , pp. 251-259
    • Zarek, P.E.1
  • 118
    • 0142137237 scopus 로고    scopus 로고
    • Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
    • Uyttenhove, C. et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9, 1269-1274 (2003).
    • (2003) Nat. Med , vol.9 , pp. 1269-1274
    • Uyttenhove, C.1
  • 119
    • 84941366350 scopus 로고    scopus 로고
    • Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses
    • Ho, P. C. et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 162, 1217-1228 (2015).
    • (2015) Cell , vol.162 , pp. 1217-1228
    • Ho, P.C.1
  • 120
    • 84948451779 scopus 로고    scopus 로고
    • Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
    • Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350, 1084-1089 (2015).
    • (2015) Science , vol.350 , pp. 1084-1089
    • Sivan, A.1
  • 121
    • 84948461699 scopus 로고    scopus 로고
    • Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
    • Vetizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079-1084 (2015).
    • (2015) Science , vol.350 , pp. 1079-1084
    • Vetizou, M.1
  • 122
    • 0033180181 scopus 로고    scopus 로고
    • Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor
    • Nishimura, H. et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11, 141-151 (1999).
    • (1999) Immunity , vol.11 , pp. 141-151
    • Nishimura, H.1
  • 123
    • 0035846991 scopus 로고    scopus 로고
    • Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
    • Nishimura, H. et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291, 319-322 (2001).
    • (2001) Science , vol.291 , pp. 319-322
    • Nishimura, H.1
  • 124
    • 0028867420 scopus 로고
    • Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
    • Tivol, E. A. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541-547 (1995).
    • (1995) Immunity , vol.3 , pp. 541-547
    • Tivol, E.A.1
  • 125
    • 0028791059 scopus 로고
    • Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4
    • Waterhouse, P. et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270, 985-988 (1995).
    • (1995) Science , vol.270 , pp. 985-988
    • Waterhouse, P.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.